Company: IMCR
Filing Date: 2025-03-17
Form Type: 424B7
Source: 0001140361-25-008917
Chunk: 35

Company: Immunocore Holdings plc
Filing Date: 2025-03-17
Form: 424B7
Chunk 35
---
 and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should read this prospectus supplement, the accompanying base prospectus, the documents that we incorporate by reference and any free writing prospectus that we have authorized for use in connection with this offering completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements.

S-20

#### TABLE OF CONTENTS

### USE OF PROCEEDS
The selling securityholders will receive all of the proceeds from the sale or other disposition of the notes or the note conversion ADSs covered by this prospectus supplement. We will not receive any of the proceeds from the sale or other disposition of the notes or the note conversion ADSs that may be offered by any of the selling securityholders.

<div align='center'>S-21</div>

TABLE OF CONTENTS

DESCRIPTION OF NOTES The following is a summary of the material terms and provisions of the notes that are being offered hereby. This summary is subject to and qualified in its entirety by the indenture (as defined below) and form of note, each of which were filed with the SEC on February 2, 2024 as an exhibit to a Current Report on Form 8-K filed by us and incorporated by reference into the registration statement of which this prospectus supplement forms a part. You should carefully review the terms and provisions of the indenture and the form of note for a complete description of the terms and conditions of the indenture and the notes. See the sections titled “Where You Can Find More Information” and “Incorporation of Certain Information by Reference” in this prospectus supplement. We issued $402.5 million aggregate principal amount of the notes under the indenture dated as of February 2, 2024, as supplemented by the first supplemental indenture, dated March 17, 2025 (the “indenture”) between us and U.S. Bank Trust Company, National Association, as trustee (the “trustee”). For purposes of this description, references to “we,” “our” and “us” refer only to Immunocore Holdings plc and not to its subsidiaries. General The notes:

| • | are our general unsecured, senior obligations; |

| • | are limited to an aggregate principal amount of $402